FierceBiotechOriginal article
{"a":[{"_":"Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday","$":{"href":"/biotech/actimed-gets-back-rights-wasting-disease-drug-ending-126m-deal-faraday","hreflang":"en"}}]}
PartnershipNeutral
AI Analysis
Summary
Actimed Therapeutics has regained full rights to its wasting disease drug from Faraday, ending a $126 million deal and securing strategic control of the asset while forfeiting potential future milestone payments.
Outcome Details
Deal termination - Actimed regained full rights to wasting disease drug from Faraday
Importance:5/10
Sentiment:
-0.20
partnership terminationrights reversionwasting diseasedeal ended
Read the original article
Published by FierceBiotech on August 6, 2026 5:09 AM